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ABSTRACT
Valproic acid (VA) is used as an anticonvulsant and is used in the treatment of bipolar 
disorder and depression. The offi cial analytical method for this drug in the compendia 
is gas chromatography, which is unavailable in many quality control laboratories. Here, 
we report a validated alternative method using high performance liquid chromatography 
with diode array detection (HPLC-DAD). The optimized parameters and conditions were 
as follows: C18 column (5 μm; 250 x 4 mm d.i.); fl ow 1.0 mL.min-1; wavelength: 210 nm; 
mobile phase: 55% acetonitrile (ACN) in water containing 0.05% v/v trifl uoroacetic acid 
(TFA) (v/v). The analytical parameters that were validated included the selectivity and 
matrix effects, linearity, repeatability and intermediate, precision, accuracy, recovery 
and robustness. This method identifi es VA unambiguously. In validation, the following 
results were obtained: good linearity in concentrations between 0.7 and 1.3 mg.mL-1 
(r2 = 0.9998), relative standard deviations (RSDs) of 0.68% for repeatability and 1.23% 
for intermediate precision, a recovery of 99.42 to 101.55% (RSD 0.14 to 0.74%) and an 
accuracy of 100.68% (RSD = 0.79%). This method is robust to small variations in procedure.
KEYWORDS: High performance liquid chromatography; HPLC-DAD; valproic acid; 
validation
RESUMO
O ácido valpróico (VA) é utilizado como anticonvulsivante e também na terapêutica da 
desordem bipolar e depressão. O método de análise deste medicamento nos compêndios 
ofi ciais é por cromatografi a gasosa e muitos laboratórios ofi ciais de controle de qualidade 
não possuem tal equipamento. A proposta deste estudo foi desenvolver e validar um método 
analítico por cromatografi a líquida de alta efi ciência acoplada com detector de conjunto 
de fotodiodos para a análise deste fármaco. Os parâmetros e condições otimizados foram: 
coluna C18 (5 μm; 250 x 4 mm d.i.), fl uxo de 1,0 mL min-1, comprimento de onda 210 nm, 
fase móvel 55% ACN e 45% solução 0,05% v/v de ácido trifl uoracético (v/v). Os parâmetros 
analíticos avaliados na validação foram: seletividade e efeito matriz, linearidade, 
repetitividade e precisão intermediária, exatidão e robustez. A metodologia desenvolvida 
mostrou identifi car de forma inequívoca o analito de interesse. No que concerne aos 
parâmetros de validação foram obtidos: faixa linear nas concentrações de 0,7 a 1,3 mg mL-1 
(r2 = 0,9998), repetitividade: desvio padrão relativo (DPR) = 0,68%, precisão intermediária: 
DPR = 1,23%, recuperação de 99,42 a 101,55% (DPR de 0,14 a 0,74%) e exatidão de 100,68% 
(DPR = 0,79%). Quando submetido a pequenas variações, a metodologia mostrou-se robusta.
PALAVRAS CHAVE: Cromatografi a líquida de alta efi ciência acoplada com detector de 
conjunto de fotodiodos; ácido valpróico; validação
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1-Introduction
Valproic acid (VA, 2-propylpentanoic acid, C8H16O2, Figure 
1) is a colorless liquid that is slightly miscible with water and 
very soluble in organic solvents and has a pKa of 4.6.1 This 
substance was fi rst approved as an anticonvulsant in the United 
States in 1978. Its properties were accidentally discovered 
when it was used as a vehicle for other anticonvulsants. VA 
is rapidly absorbed orally, attaining maximal blood levels one 
to four hours after the administration of 250 mg. It is quickly 
distributed to tissues and binds strongly to human plasma 
proteins (90%). Metabolism occurs mainly in the liver (95%); 
less than 5% is excreted intact.
VA is indicated as monotherapy for absence crises, 
myoclonus, partial and tonic-clonic seizures,2 and myoclonic 
juvenile epilepsy. However, some systemic toxicity has 
been observed.3 VA is also used as an alternative to lithium 
in patients with bipolar disorder, as well as in depression, 
migraine, febrile convulsions and to treat brain tumor (alone 
or in combination with other anticonvulsants).4,5
The analytical technique recommended by the US 
Pharmacopoeia for analyzing VA capsules is gas chromatography 
(CG).6 However, it is important to note that some of these methods 
require a derivatization step, which is time consuming and has a 
detrimental effect on performance. Several laboratories use HPLC 
to analyze anticonvulsants with chemical properties that are very 
similar to VA. Therefore, this study is intended to develop and 
validate a rapid, simple and effective alternative method using 
HPLC-DAD to analyze VA in pharmaceutical formulations.
2- Experimental
2.1 - Reagents
All solutions used in this study were prepared with ultrapure 
water using a Milli-Q® (Millipore) system. Acetonitrile (for liquid 
chromatography), sodium hydroxide (Pure Analysis, PA) and 
boric acid (Pure Analysis, PA) were purchased from Vetec (Rio 
de Janeiro, Brazil). Trifl uoroacetic, acetic and phosphoric acids 
(all Pure Analysis, PA) were purchased from Merck (Darmstadt, 
Germany). A reference sample of valproic acid was donated by 
ABBOTT laboratory (purity 100.17%). VA capsules (250 mg) were 
used as a reference for methodological and validation studies. 
Mobile phase components were degassed using sonication under 
reduced pressure for 10 min before use. All solutions were 
fi ltered using Tefl on® 0.22 μm membranes.
 2.2 - Equipments
The following equipments were used: (1) high performance 
liquid chromatograph (Young Lin), with an ultraviolet-visible 
diode array detector (HPLC-DAD; Hogye, Korea), (2) high 
performance liquid chromatograph (Varian) with ultraviolet-
visible detector (HPLC-UV; California, United States), (3) 
Sonicator (Nova Ética, São Paulo, Brazil), (4) analytical 
balance (Mettler Toledo A204, São Paulo, Brazil), (5) pH meter 
(Micronal, São Paulo, Brazil). A Lichrospher® C18 column (5 
m; 250 x 4 mm d.i.) was used during for validation studies, 
and Hypersil BDS C18 (5 m; 250 x 4 mm d.i.) was used for 
robustness tests. Data were acquired with Star Workstation 
Version 5.5 software (Varian®).
2.3 – Chromatographic  Conditions
The chromatographic conditions were based on those 
reported by Amini.7 The optimal analytical conditions were a 
mobile phase of 55% acetonitrile (ACN) in water containing 0.05% 
v/v trifl uoroacetic acid (TFA) (v/v) (pH 2.3); fl ow: 1 mL.min-1; 
column Lichrospher® C18 (5m; 250 x 4 mm d.i.); wavelength: 
210 nm; injection volume: 25 μL; and temperature: 25 °C.
2.4 – Preparation of standard and samples
2.4.1-  Standard preparation 
Stock solutions of VA were prepared in the mobile phase 
mixture described under “chromatographic conditions” at 
a concentration of 1.03 mg.mL-1. Working standard solutions 
were obtained by diluting aliquots of each stock solution in the 
same mixture. All solutions were sonicated for 30 min before 
use and were stirred every 5 min during use.
2.4.2- Preparation of blank solution 
The blank solution was prepared from all of the substances 
in the capsule except VA. The quantities of these substances 
were as specifi ed in each formulation8. The blank solution was 
prepared in the mobile phase described under “chromatographic 
conditions”. The solution was sonicated for 30 min and was then 
stirred every 5 min. The solution was fi ltered through Tefl on® 
0.45 μm membranes and analyzed in triplicate.
2.4.3- Sample preparation
The standard solution of VA was added to the blank 
solution to give a nominal concentration of 1.00 mg.mL-1.
2.4.4- Preparation of the pharmaceutical formulation 
After validating the method, 3 samples containing 
approximately 1.00 mg.mL-1 of VA from 250 mg capsules 
(medications A (lot 710098F01), B (lot 850758F01) and C (lot 
809707)) were analyzed. 
Three samples from each formulation (A and B) were prepared 
by weighing and homogenizing ten capsules from each lot. This 
mixture was weighed; after dilution, the mobile phase contained 
approximately 1.00 mg.mL-1 of VA. The samples were sonicated 
for 30 min and were then stirred every 5 min. The samples were 
fi ltered through Tefl on® 0.45 μm membranes and analyzed in 
triplicate by comparison with the analytical curve (curve 1).
2.5 - System Adequacy
To evaluate the adequacy of these parameters, 
standard and sample solutions were prepared in triplicate in 
concentrations of 1.03 mg.mL-1 and 1.00 mg.mL-1, respectively. 
The mobile phase was used as solvent as described above. The 
solutions were sonicated for 30 min and were stirred every 5 
min when in use.
2.6 – Stability Study of Sample and Standard Solutions
The standard solution of valproic acid (1.03 mg.mL-1) was 
analyzed immediately after preparation, after 6, 12, 24, 48, 
and 72 hours, and fi nally after one week. The sample solution 
(1.00 mg.mL-1) was evaluated 1, 2, 3, 4, 5, 6, and 24 hours after 
preparation. Both solutions were stored at room temperature 
(25 °C) in the dark. 
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2.7 – Validation Procedure
As this method falls under category I (quantifi cation of 
the main component)10, validation requires evaluating the 
following parameters: selectivity – matrix effect, linearity, 
linear work range, accuracy, recovery, precision (repeatability 
and intermediate precision), and robustness.9,10 The 
acceptance criteria and recommendations for most parameters 
are given in the Results and Discussion sections. All equipment, 
instruments, and glass utilized in the validation were qualifi ed 
and/or calibrated according to ISOGUIDE 17025, and standard 
operating procedures were used.
2.7.1 - Selectivity and matrix effects
Selectivity and matrix effects were evaluated by comparing 
the chromatograms for the blank and sample solutions (1.00 
mg.mL-1) at the retention time (tR) of the peak observed for 
the standard VA solution. 
2.7.2 – Linear Work Range
The linear work range was established as per Sousa and 
Junqueira (2005), who stated that the percentage of the 
analyte contained in the linearity range should vary from 70 to 
130% of the theoretical concentration.11
2.7.3 - Linearity
Triplicate samples of VA standard solutions (curve 1) and 
sample solutions (blank fortifi ed with VA, curve 2) of 0.7, 
0.8, 0.9, 1.0,1.1, 1.2, and 1.3 mg.mL-1 were used. The steps 
used for linear evaluation were as follows: (i) determining the 
concentration range of interest, considering the application 
and that the expected concentrations of the samples should be 
close to the center of this range, and (ii) preparing an analytical 
curve using standard solutions at seven concentrations from 
70 to 130%, with three independent replicates for each 
concentration and aleatory injections of these solutions into 
the HPLC-DAD System.11 
Evaluating the linearity involved using the ordinary 
minimum squares method (OMSM), and the regression 
parameters and treatments of extreme values were evaluated 
as described below. (i) Determination of chromatographic peak 
areas relative to the valproic acid peak. (ii) Estimation of the 
slope, intersect, residuals, variances and r2. (iii) Exclusion of 
extreme values using the Jackknife method for standardized 
residuals.11 The third step also involved verifying the regression 
residuals and adjusting the linear model as follows. (i) Residual 
normality was adjusted by the Ryan-Joiner test; (ii) residual 
independence was adjusted by the Durbin-Watson test; (iii) 
residual homoscedasticity was adjusted by the Brown-Forsythe 
test; and (iv) the signifi cance of the regression was verifi ed and 
the linear model was adjusted by variance analysis (ANOVA).11 
The software used was Microsoft Offi ce Excel® 2007. 
2.7.4 – Precision (Repeatability and Intermediate 
Precision)
2.7.4.1 - Repeatability
Thirty determinations were made for the sample solution 
(1.00 mg.mL-1) by the same analyst on the same day using the 
curve obtained from the standard VA solution (curve 1). The 
concentration and relative standard deviation were calculated.
2.7.4.2 – Intermediate Precision
Ten analyses of the same sample solution (1.00 mg.mL-1) 
were performed by three analysts in the same laboratory using 
the same method on different days and different equipment, 
using the curve obtained from the standard VA solution (curve 
1), prepared recently. The obtained results were evaluated 
using the intermediate precision standard deviation (Spi).
2.7.5 - Accuracy
Samples were prepared by adding the standard VA solution 
to the blank solution, giving concentrations of approximately 
0.7, 0.8, 0.9, 1.0, 1.1, 1.2, and 1.3 mg.mL-1, in triplicate. 
These solutions were analyzed using the analytical curve 
(curve 1). Accuracy and RSD averages were calculated.
2.7.6 – Recovery
Capsules containing 250 mg of VA were analyzed using 
the calibration curve (curve 1: 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 
and 1.3 mg.mL-1 of VA); after this, the medication was 
added to the standard solution of VA and diluted in the same 
concentrations using this curve.  Recovery and RSD were 
calculated for each concentration.
2.7.7 – Robustness
Eight combinations were assayed (Table 1) during method 
development, with seven parameters varied: time in the 
ultrasonic bath (20 or 30 min), column manufacturer (Merck 
or Supelco), mobile phase composition (55:45 or 60:40 of 
acetonitrile and TFA 0.05%, respectively), fl ow (1.0 or 1.2 
mL.min-1), column oven temperature (25 or 30 ºC), pH (2.3 or 
2.6), and stirring (present or absent).
The effect on the adequacy parameters of the 
chromatographic system (i.e., the number of theoretical 
plates and the asymmetry factor) was calculated for each of 
the seven variables in Table 1. The analyses were performed 
under normal and modifi ed conditions. The Youden test was 
applied to evaluate the infl uence of each variation.9
Table 1- The eight combinations of conditions evaluated for 
robustness using the Youden test 
Robustness test
Parameters Condition 1 Condition 2 Condition 3 Condition 4
Time at 
ultrasound
30 min 30 min 30 min 30 min
Column Merck Merck Supelco Supelco
Mobile phase 55:45 60:40 55:45 60:40
Flow 1.0 1.0 1.2 1.2
Temperature 25 ºC 30 ºC 25 ºC 30 ºC
pH 2.3 2.6 2.6 2.3
Stirring Present Absent Absent Present
Condition 5 Condition 6 Condition 7 Condition 8
Time at 
ultrasound
20 min 20 min 20 min 20 min
Column Merck Merck Supelco Supelco
Mobile phase 55:45 60:40 55:45 60:40
Flow 1.2 1.2 1.0 1.0
Temperature 30 ºC 25 ºC 30 ºC 25 ºC
pH 2.3 2.6 2.6 2.3
Stirring Absent Present Present Absent
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3- Results and Discussions
3.1 – Method Development and Validation
Figure 1 shows the typical HPLC-DAD chromatograms 
obtained for the standard VA solution and a pharmaceutical 
preparation. In both cases, a well defi ned chromatographic 
peak was obtained (tR 5.7 min). The total run time was 10 min.
The retention times of the sample (1.00 mg.mL-1 VA) and 
standard solutions (1.03 mg.mL-1 VA) in triplicate were 5.70 
min (RSD 0.06%) and 5.73 min (RSD 0.04%), respectively. The 
asymmetry factors obtained for the sample and standard VA 
peaks (1.07 (RSD 0.2%) and 1.06 (RSD 0.5%), respectively) 
are within the limits described in the recent literature. The 
number of theoretical plates (5397 (RSD 0.1%) and 5619 (RSD 
1.2%), respectively) are also well above the minimal value of 
2000 theoretical plates, thus confi rming the effi ciency of the 
chromatographic system. The RSD values for the comparison of 
the VA peak areas (0.35% and 0.43%, respectively) indicate that 
repeatability falls within the specifi cations of the 2% test.12 
These values indicate that the parameters used were adequate 
for analytical purposes; i.e., this method is suitable for the 
determination of VA in pharmaceutical formulations.
The sample and standard solutions were freshly prepared, 
and the VA peak areas were determined over time. The sample 
solution was analyzed at a concentration of 1.0 mg.mL-1 
over 24 hours. The initial area was 766 mV.s, and the range 
over this time was from 759 to 772 mV.s, with an average of 
764.8 mV.s (DPR 0.57%). The standard solution was analyzed 
at a concentration of 1.03 mg.mL-1 over 7 days. The initial 
area was 826 mV.s, and the range was from 816 to 823 mV.s: a 
difference of 1.2% existed between the lowest and the initial 
values. The average over the week was 821 mV.s (DPR 0.44%). 
Sharbir (2003)12 reported a variation of up to 2.0% compared to 
the freshly prepared sample. These results show no signifi cant 
decrease in the peak area of the standard solution over 7 
days. Thus, the solution can be stored for this period without 
affecting the reliability of the results. 
To evaluate the selectivity, the UV absorption spectra 
of the sample and standard were recorded (Figures 2A-2C). 
Comparing the spectra before (A), during (B), and after (C) 
the retention time of VA, it is possible to verify that the UV 
spectra obtained during elution (B) are very similar. There 
is also no detectable co-eluting compound present in the 
sample (A and C).
Confi rming the absence of any matrix interference or 
interference from other constituents of the pharmaceutical 
preparation, no evidence of co-elution was observed (Figure 
3). A comparison of the chromatograms of the blank to the 
reference formulation unequivocally shows that the other 
signals are due to excipients and that they are not coincident 
with the VA signal. However, this applies only to the tested 
matrix (e.g., corn oil, propylparaben, methylparaben, 
glycerin, deionized water, titanium dioxide, gelatin, yellow 
dusk dye and mineral oil). Other matrices may exhibit different 
chromatographic behaviors.13
Figure 1 – HPLC-DAD chromatograms of VA at (A) 1.03 mg.mL-1 in the standard solution and (B) 1.00 mg.mL-1, prepared using the 
sample solution. Analytical conditions: Lichrospher C18 column (5 m; 250 x 4 mm d.i.), mobile phase: 45:55 [aqueous trifl uoroacetic 
acid 0.05% v/v (pH 2.3):acetonitrile], fl ow: 1.0 mL.min-1, wavelength: 210 nm, temperature: 25 ºC, injection volume: 25 μL.
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Regarding linearity, the results show that the calibration 
curve for VA is linear from 0.7 to 1.3 mg.mL-1 (y (mAU) = 766 x 
(mg.mL-1) + 2.08, r2 0.9998). 
In applying the Jackknife test, no aberrant value was 
identifi ed. The Ryan-Joiner test was utilized to verify the 
normal distribution of the residuals, which was confi rmed 
(Req 0.99 > Rcrit (α= 0.05) 0.95). The Levene t statistic 
showed homoscedastic behavior (p= 0.849 > 0.05). The 
Durbin-Watson test confi rmed the independence of 
regression residuals [d (calculated)= 2.15 > dU (Upper limit 
- α= 0.05)= 1.42].11
Repeatability was confi rmed over 30 determinations 
(average 0.998 mg.mL-1, repeatability relative standard 
deviation (rRSD) 0.68%). According to Sharbir,12 the maximal 
acceptable rRSD limit value is 2.0%. The values that we 
obtained were signifi cantly lower than this criterion.
The intermediate precision standard deviation (Spi) 
was 1.23%, proving the method’s internal reproducibility. 
According to Horwitz,14 the maximal value for Spi as a function 
of the drug concentration is 5.6%. The results obtained for ten 
analyses of the same solutions (1.00 mg.mL-1 of VA) by three 
different analysts, using the curve for the standard VA solution 
(curve 1), are shown in Table 2.
Figure 2 – Absorption spectra in the ultraviolet region of the (I) sample solution (1.00 mg.mL-1) and (II) standard VA solution 
(1.03 mg.mL-1) before (A), during (B), and after (C) the retention time of VA.
Figure 3- Chromatograms of (1) blank and (2) sample solution (1.00 mg.mL-1 of VA). Analytical conditions: Lichrospher C18 column 
(5 m; 250 x 4 mm d.i.), mobile phase: 45:55 [aqueous trifl uoroacetic acid 0.05% v/v (pH 2.3):acetonitrile], fl ow: 1.0 mL.min-1, 
wavelength: 210 nm, temperature: 25 ºC, injection volume: 25 μL.
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The average accuracy was 100.68% (RSD 0.79%). Recovery 
varied from 99.42 to 101.55%, and the RSD varied from 
0.14 to 0.74%. According to Horwitz,14 the recovery limit 
may vary between 95 and 105% of the value claimed by the 
manufacturer (Table 3).
Robustness was evaluated according to the system 
adequacy parameters. The infl uence of each variation on area 
repeatability, tail factor, number of the theoretical plates, and 
retention factor was verifi ed.
Relative standard deviations for 8 combinations varied 
from 0.11 to 1.44%, which was satisfactory (the maximum 
permissible value for this parameter is 2%).12
Tail factors varied from 1.05 to 1.48. Because these values 
were all below 2, symmetry was within acceptable limits.6
Retention factors were between 2.8 and 4.7; column dead 
volume differentiation was thus satisfactory. According to 
Harris,15 acceptable values are between 2 and 10.
The number of theoretical plates varied from 4181 to 6680, 
which was higher than the value recommended by Sharbir12 
(N>2,000). This suggests that the column used was adequate. 
Thus, this method is robust to the variations listed in Table 1.
3.2 – Analysis of Pharmaceutical Formulations
The results of contents for the analysis of pharmaceutical 
preparations A, B, and C were: 99.82% (RSD 0.34%), 104.58% 
(RSD 0.34%) and 101.68% (RSD 0.48%), respectively. Compared 
with the recommendations of USP 33 (90 to 110% of the 
value claimed by the manufacturer), we conclude that these 
formulations are satisfactory.
4 - Conclusions
This validated method permits the rapid, effi cient and 
robust analysis of VA. Validation demonstrates that the method 
permits the reliable and unambiguous identifi cation and 
quantifi cation of VA. The method also exhibits satisfactory 
selectivity, linearity, precision (repeatability and intermediate 
precision), accuracy, recovery and robustness. The validation 
procedures extended over 3 months. Throughout this period, all 
of the reagents gave satisfactory results. This technique could 
also be applied for the determination of sodium valproate in 
syrup, provided the samples were acidifi ed with 1 mL of aqueous 
trifl uoroacetic acid (0.05% v/v). The VA capsules and syrup 
tested met UPS 33 specifi cations. This method will be useful 
in the quality control of medications containing VA because 
most offi cial quality control laboratories do not have the gas 
chromatograph required for the United States Pharmacopoeia 
(USP) method and thus use liquid chromatography instead.
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